# Arjun V. Balar

Source: https://onco.cc/people/arjun-balar/  
OnCo record `arjun-balar` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led KEYNOTE-052 and IMvigor210 cohort 1, establishing first-line immunotherapy for cisplatin-ineligible bladder cancer.

## Summary

Arjun Balar led KEYNOTE-052 and the cisplatin-ineligible cohort of IMvigor210, the studies that gave pembrolizumab and atezolizumab their first-line approvals in urothelial cancer for patients who cannot receive cisplatin, and KEYNOTE-057 in BCG-unresponsive non-muscle-invasive disease. He continues to lead combination and bladder-preservation trials at NYU.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: urothelial; immunotherapy
- Role: Professor of Medicine and Director, Genitourinary Medical Oncology Program, NYU Langone Perlmutter Cancer Center
- Specialisms: Urothelial cancer; First-line immunotherapy; Non-muscle-invasive bladder cancer; Combination therapy

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Balar%20AV%5BAuthor%5D%20urothelial%20pembrolizumab

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [PD-1](https://onco.cc/targets/pd1/), [PD-L1](https://onco.cc/targets/pdl1/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- institutions: [Laura and Isaac Perlmutter Cancer Center at NYU Langone Health](https://onco.cc/institutions/nyu-perlmutter/)
- trials: [KEYNOTE-057](https://onco.cc/trials/keynote-057/)

---
JSON: https://onco.cc/api/v1/entities/arjun-balar.json